Therefore, it is possible that NOD2 activation in KCs and DCs protects mice from hepatocarcinogenesis and metabolic syndrome, whereas NOD2 activation in hepatocytes promotes oncogenesis (51). The gene discussed is NOD2; the disease is metabolic syndrome.